Helogen, a New York-based space biotechnology startup, raised $7.1 million in seed funding co-led by RRE Ventures and Oceans, with participation from One Way Ventures and Blisce. The company develops automated laboratory hardware and robotic manufacturing equipment that operates in microgravity to synthesise advanced biomaterials for medical implants. Its platform uses remote-controlled bioreactors and crystallisation chambers inside orbiting satellite modules, leveraging the weightless environment of space to achieve near-perfect molecular structures and material purity. Led by chief executive officer Shishir Bankapur, Helogen will use the capital to scale its automated in-orbit fabrication hardware, expand its aerospace engineering and molecular biology teams, and accelerate customer-funded biological research programmes. The cloud-linked system provides biopharma enterprises and academic research teams with commercial access to design next-generation medical implants.

Helogen Corporation has acquired Vellon Space, a Bengaluru-based startup, to expand its reach into India's space and biotechnology sectors. The acquisition aims to leverage Vellon's expertise and collaborations with ISRO and other institutions to offer advanced orbital biomanufacturing and drug development technologies. India's pharmaceutical market, valued at $58 billion, is projected to reach $120–130 billion by 2030. The terms of the transaction remain confidential.